Introduction
============

The adaptation of cells and organisms to the environment requires coordinate and rapid response to external stimuli and stress. In order to do so, throughout evolution cells developed complex molecular mechanisms that directly influence gene regulation without changing the DNA sequence. These mechanisms, also called epigenetic regulation, modify the chromatin composition and structure. The exchange of replication-coupled histones for histone variants is one of the major chromatin modifications. Histone variants differ from replication-coupled canonical histones in their protein structure, timing of expression, and genomic distribution ([@B9]). Depending on the cellular context, they are incorporated into chromatin in a locus-specific manner by specialized protein chaperones and ATP-dependent chromatin remodeling enzymes. In this way, histone variant incorporation endows chromatin with particular properties. During the last years, it has become clear that histone variants play key roles in epigenetically regulated processes such as development, cancer, and somatic cell reprogramming ([@B9]). Within a diverse group of H2A variants, macroH2As are the most divergent group of histone variants with a unique tripartite structure ([@B8]). The hallmark of macroH2A structure is its evolutionary conserved C-terminal macrodomain. Intriguingly, this macrodomain mediates the interaction of the macroH2A1.1 isoform with poly-ADP-ribose polymerase 1 (PARP1) enzyme, which is a nuclear stress sensor ([@B43]). Here, we will discuss the effect of this interaction on cell physiology with a particular focus on stress response and cell metabolism. We believe that a better understanding of the macroH2A1.1-PARP1 axis will help to interpret reported loss- and gain-of-function phenotypes.

Presenting the Players
======================

MacroH2A1.1 -- A Structural Chromatin Component Able to Bind ADP-Ribose
-----------------------------------------------------------------------

MacroH2A histone variants are highly conserved since the emergence of multicellular life ([@B69]). They are widely distributed across the genome and make up approximately 1% of the total H2A pool ([@B9]). In mammals, two genes, H2AFY and H2AFY2, encode for macroH2A1 and macroH2A2, respectively ([@B63]; [@B25]). Alternative splicing of macroH2A1 further gives rise to macroH2A1.1 and macroH2A1.2 isoforms ([@B62]). MacroH2As are unique for their atypical tripartite protein structure comprised of an N-terminal H2A-like domain, which is fused by an unstructured linker region to a large C-terminal macrodomain ([@B14]; [@B43]). It was recently demonstrated that macroH2A plays a major structural role in the maintenance of heterochromatin architecture and nuclear organization ([@B35]; [@B29]). While macroH2A has a role in transcriptional repression ([@B24]; [@B53]), it is also involved in signal-induced gene activation (discussed in [@B26]) and in suppressing transcriptional noise ([@B46]). In this way, macroH2A directly or indirectly affects transcriptional regulation in an ambivalent manner.

Loss-of-function studies have shown that macroH2A promotes differentiation of embryonic and adult stem cells ([@B58]) and inhibits somatic cell reprogramming ([@B57]). While macroH2As contribute to the robustness of embryonic development in zebrafish ([@B10]), mice lacking a single macroH2A gene develop without overt developmental defects and are viable and fertile ([@B16]; [@B6]). On the other hand, mice lacking both macroH2A-encoding genes are growth retarded ([@B61]). In cancer, macroH2A1.1 and macroH2A2 mostly act as tumor suppressors, while the role of macroH2A1.2 seems to be largely context- and cell type- dependent ([@B12]; [@B23]).

It remains unclear if the macrodomain of macroH2A is involved in the general function of the protein. Crystal structures of macroH2A macrodomains revealed the presence of a binding pocket within all isoforms. Nevertheless, these binding pockets differ significantly in size and hydrophobicity ([@B43]). Generally, macrodomains can be found across most species ([@B68]). They are ancient globular domains that are able to bind ADP-ribose moieties and derivatives (reviewed in [@B66]). Ladurner group made a pioneering discovery showing that macroH2A1.1 macrodomain also specifically binds nicotinamide adenine dinucleotide (NAD^+^) derived metabolites such as ADP-ribose and *O*-acetyl-ADP-ribose ([@B43]). This binding of ADP-ribose enables macroH2A1.1 to interact with activated PARP1 enzyme ([@B40]; [@B79]). On the other hand, macroH2A1.2 and macroH2A2 isoforms are unable to bind these metabolites.

PARP1 -- A Major Nuclear Stress Sensor of the Cell
--------------------------------------------------

Poly-ADP-ribose polymerases, also known as diphteria toxin-like ADP-ribosyltransferases (ARTDs), are a conserved superfamily of enzymes present in all domains of life, from bacteria to human ([@B21]; [@B27]). In mammals, up to 17 PARP genes share specific signature motifs in the catalytic domain ([@B49]). PARPs are stress sensor enzymes that are best studied in the context of DNA damage repair (reviewed in [@B2]), transcription, and chromatin organization (reviewed in [@B42]). On the whole-cell level, PARPs regulate several cellular processes including proliferation and differentiation, apoptosis, pro-inflammatory responses, neuronal long-term memory, mitochondrial function, and metabolic stress (for reviews, please see [@B19]; [@B73]; [@B45]; [@B81]).

Poly-ADP-ribose polymerase 1 is the founding and the best characterized member of the PARP superfamily ([@B1]). It is highly abundant in eukaryote nuclei and one of three nuclear PARPs that are activated by discontinuous DNA structures caused by DNA damage. Indeed, PARP1 is implicated in the repair of single-strand or double-strand breaks either by homologous recombination or non-homologous end joining (reviewed in [@B70]). When activated, PARP1 hydrolyzes NAD^+^ generating ADP-ribose moieties (reviewed in [@B73]). Consequently, PARP1 transfers this newly formed ADP-ribose to target proteins resulting in mono- or poly-ADP-ribosylation (MARylation and PARylation, respectively). The main targets of activated PARP1 are histones and PARP1 itself, as a consequence of auto-PARylation (reviewed in [@B41]).

Poly-ADP-ribose polymerase 1 is composed of three functional domains, namely, N-terminal DNA-binding domain, central auto-modification domain, and C-terminal catalytic domain ([@B44]). The binding to damaged DNA mediates conformational change of PARP1 increasing its affinity for NAD^+^ and leading to the activation of PARP1 catalytic domain. PAR formation has at least three functions: (i) creation of a platform for the recruitment of effector proteins including the DNA repair machinery, (ii) disruption of protein-protein or protein-nucleic acid interactions leading to chromatin relaxation, and (iii) generation of signal for protein ubiquitination and degradation (reviewed in [@B37]). Auto-PARylation of PARP1 reduces its affinity toward DNA creating a negative feedback loop which inhibits its own activity ([@B90]). Removal of PARP1 from DNA and rapid enzymatic turnover of PAR are essential for optimal function of the DNA repair machinery (reviewed in [@B70]). Interestingly, it has been reported that PARP1 can also be activated in a DNA-independent manner through the interaction with ERK2 (extracellular signal-regulated kinase 2) ([@B22]). Therefore, this may implicate PARP enzymes in other cellular processes unrelated to DNA, opening new lines of research in the field of PARP.

*In vivo* studies showed that mice lacking PARP1 are hypersensitive to genotoxic agents or γ-irradiation, demonstrating the importance of PARP1 for efficient DNA repair ([@B52]; [@B85]). Pharmacological inhibition of PARP1 was first introduced in cancer therapy to exploit synthetic lethality of BRCA1-deficient breast tumors ([@B33]) and is now widely tested in combination with DNA damaging chemotherapeutic drugs ([@B32]). In addition to cancer therapy, PARP inhibitors may have additional benefits in other diseases such as cardiovascular or metabolic disorders ([@B56]; [@B75]).

Physiological Studies Link MacroH2A1 and PARP1 to Metabolism
------------------------------------------------------------

Systemic loss-of-function studies in mice linked both macroH2A1 and PARP1 to metabolic phenotypes, although some observations are controversial and sometimes lead to opposite conclusions. Here, we summarize and discuss some of these findings (for a more comprehensive view, please see **Table [1](#T1){ref-type="table"}**).

###### 

Impact of macroH2A1.1-PARP1 axis on metabolic phenotypes.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                         Model system                               Metabolic phenotype   Reference                                                                                                                                                                                                         
  ----------- -------------------------- ------------------------------------------ --------------------- --------------- ------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------ ---------- ----------------
  MacroH2A1   Loss or gain of function   C57BL/6 mice                               Mainly Male           From 1 to 8     MacroH2A1 KO                          Fertile and viable, develop glucose intolerance. Deregulation of genes involved in liver metabolism during new born-adult transition.            Negative   [@B16]

                                         129Vx C57BL/6 mice                         Female                From 6 to 12    MacroH2A1 KO                          50% exacerbated liver steatosis.                                                                                                                 Negative   [@B6]

                                         129Vx C57BL/6 mice                         Mainly Male           From 1 to 8     MacroH2A1 double KO                   Smaller with reduced lean body mass.\                                                                                                            Negative   [@B61]
                                                                                                                                                                More susceptible to perinatal death, reproductive, and mothering troubles.\                                                                                 
                                                                                                                                                                Deregulation of genes involved in liver metabolism.                                                                                                         

                                         129Vx C57BL/6 mice                         Male                  From 12 to 24   MacroH2A1 KO                          Fat mass reduction and protected against HFD-induced obesity.\                                                                                   Positive   [@B74]
                                                                                                                                                                Up-regulation of thermogenic genes, downregulation of adipogenic genes.\                                                                                    
                                                                                                                                                                Enhance glucose tolerance, increase of total activity during nights.                                                                                        

                                         C57BL/6                                    Male                  From 6 to 18    MacroH2A1.2 gain of function          Increased leaness, glucose tolerance, decrease fat accumulation in the liver and pancreas.                                                       Positive   [@B60]

                                         human HepG2 hepatocytes cell line          Male-derived          /               MacroH2A1.2 overexpression            Activation of lipogenic genes, enhanced lipid uptake, and triglycerides.                                                                         Negative   [@B65]

                                         human HepG2 hepatocytes cell line          Male-derived          /               MacroH2A1.1 overexpression            Protected against lipid accumulation with reduction of triglycerides.                                                                            Positive   

                                         human HepG2 and murine Hepa1-6 cell line   Male-derived          /               MacroH2A1.1 overexpression            Protected hepatocytes against lipid accumulation.                                                                                                Positive   [@B59]

                                         murine 3T3-L1 adipocytes cell line         Male-derived          /               MacroH2A1.1 downregulation (shRNAs)   Adipogenesis abrogation via EZH2 interaction and regulation of Wnt signaling.                                                                    Positive   [@B84]

                                         murine C2C12 myotubes cell line            Female-derived        /               MacroH2A1.1 downregulation (siRNAs)   Altered mitochondrial activity, mitochondrial NAD^+^ and NMN depletion.                                                                          Negative   [@B67]

                                                                                                                                                                                                                                                                                                                            

  PARP1       Loss or gain of function   C57BL/6 mice                               Male                  From 0 to 46    PARP1 KO                              Lower body weight gain with HFD.\                                                                                                                Positive   [@B5]; [@B30]
                                                                                                                                                                Increased energy expenditure and higher glucose tolerance.\                                                                                                 
                                                                                                                                                                Better glucose clearance and decrease of FFA and Triglycerides.                                                                                             

                                         C57BL/6 mice                               Male                  From 0 to 13    PARP1 KO                              Increased of hepatic steatosis.                                                                                                                  Negative   [@B30]

                                         C57BL/6 mice                               Male                  From 4 to 46    PARP1 KO                              Increased of mitochondrial biogenesis and NAD^+^ content via SIRT1 activity.                                                                     Positive   [@B5]

                                         C57BL/6 mice                               Not indicated         Not indicated   PARP1 KO                              Altered circadian rhythms and food intake.                                                                                                       Negative   [@B3],

                                         C57B1/6 mice                               Not indicated         Not indicated   Ectopic integration of human PARP1    Premature development of inflammation and age-associated pathologies. Gain weight and glucose intolerance.                                       Negative   [@B51]

                                                                                                                                                                                                                                                                                                                            

  PARP1       Loss or gain of function   129/SvlmJ mice 129VxC57BL/6 mice           Mainly male           From 4 to 19    PARP1 KO                              Gain weight; and increased susceptibility to high-fat diet-induced obesity. Hyperglycemia, hyperinsulinemia, increase of plasma leptin levels.   Negative   [@B85]; [@B28]

                                                                                                                                                                Increase of fat mass and decrease of lean mass.                                                                                                             

                                         129Vx C57BL/6 mice                         Not indicated         From 4 to 10    PARP1 KO                              Protection against streptozotocin diabetes.                                                                                                      Positive   [@B7]

                                         129Vx C57BL/6 mice                         Not indicated         20              PARP1 KO                              Protection against *Trypanpsoma cruzi*-induced cardiomyopathy.\                                                                                  Positive   [@B86]
                                                                                                                                                                Improve mtDNA content, mitochondrial activity and oxidative stress.                                                                                         

                                         mice (unclear from Jackson laboratory)     Male                  From 4 to 48    PARP1 KO                              Prevented drastic decrease of β-cell proliferation during aging.                                                                                 Positive   [@B36]

                                         human HEK293T kidney cells                 Female-derived        /               PARP1 KO                              Enhanced mitochondrial gene expression and respiration.                                                                                          Positive   [@B5];

                                         murine 3T3-L1 adipocytes                   Male-derived          /               PARP1 KO                              Reduced adipocyte differentiation and PPARy-dependent gene expression.                                                                           Positive   [@B31]; [@B48]

                                         murine C2C12                               Male-derived          /               PARP1 KO                              Increase of adipogenic transcriptional program through C/EBPβ PARylation.                                                                        Negative   [@B50]

                                         murine C2C12 myotubes cell line            Female-derived        /               PARP1 siRNA                           Increased oxidative phosphorylation and glycolytic activity.                                                                                     Positive   [@B54]

  PARP1       Inhibition                 C57BL/6 mice                               Male                  From 4 to 46    Inhibition (PJ34)                     Better lipid metabolic profile, increase of NAD^+^ level in Brown adipose tissue and skeletal muscle.                                            Positive   [@B5]

                                         C57BL/6 mice                               Not indicated         20              Inhibition (PJ34)                     Enhanced mitochondrial biogenesis in Chagas mice with myocardial fibrosis.                                                                       Positive   [@B86]

                                         C57BL/6 mice                               Male                  From 10 to 28   Inhibition (MRL-45696)                Enhanced mitochondrial content and activity in Brown adipose tissue and skeletal muscle.                                                         Positive   [@B64]

                                         129Vx C57BL/6 mice                         Not indicated         Not indicated   Inhibition (nicotinamide)             Prevented pancreatic β-cell destruction.                                                                                                         Positive   [@B7]

                                         Wistar rat                                 Male                  Not indicated   Inhibition (nicotinamide, or 3-ABA)   Improved β-cell regeneration and prevents diabetes mellitus.                                                                                     Positive   [@B89]

                                         diabetic db/db(Leprdb/db) mice             Male                  5               Inhibition (lNO1001; PJ34)            Prevented diabetes induces podocytes and blocks their hyperglycemia.                                                                             Positive   [@B77]

                                         murine C2C12 myotubes cell line            Female-derived        /               Inhibition (PJ34)                     Better mitochondrial activity and enhanced oxidative metabolism.                                                                                 Positive   [@B5]; [@B67]
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The table summarizes the different metabolic phenotypes observed when PARP1 or macroH2A1s are modulated

in vivo

and

in vitro

. Positive or negative outcomes from such manipulation are shown in the outcome section

.

Although mice lacking macroH2As display only mild phenotypes, they repeatedly exhibit metabolic disorders. Indeed, macroH2A1 knockout (KO) mice displayed impaired clearance of bolus glucose injections, suggesting a pre-diabetic phenotype and partial insulin resistance ([@B16]). However, when fed with high-fat diet, increased energy expenditure was observed and was accompanied by lower accumulation of fat and increased leanness ([@B74]). Furthermore, deregulation of genes involved in lipid metabolism was reported in the liver of mice from different genetic backgrounds ([@B16]; [@B6]). However, liver fat accumulation was only observed in female mice with 50% penetrance ([@B6]). Liver cancer cell lines showed to be protected from lipid accumulation upon overexpression of macroH2A1.1 ([@B59]). Moreover, overexpression of macroH2A1.2 in mice was found to reduce adipose tissue and thus to promote leanness ([@B60]). In summary, macroH2A has been reported as a metabolic regulator with opposing effects in mice. Such discrepancies might be explained by the use of mice with different genetic backgrounds, ages or genders and distinct outcomes can be observed depending on the macroH2A isoforms depleted (**Table [1](#T1){ref-type="table"}**).

Similarly to macroH2A1, contradictory results have been observed with PARP1 KO mice, displaying improved or deteriorated metabolic fitness (reviewed in [@B4]; **Table [1](#T1){ref-type="table"}**). On the one hand, mice lacking PARP1 displayed aberrant circadian rhythms ([@B3]) and diet-induced obesity ([@B28]) associated with hepatic steatosis ([@B30]). On the other hand, PARP1 inhibition and deletion in mice were associated with improvement of diabetes- or obesity-related parameters such as glucose tolerance, weight loss, or fat mass reduction (reviewed in [@B4]; **Table [1](#T1){ref-type="table"}**). Furthermore, PARP1 depletion is correlated with improved mitochondrial and heart function ([@B86]). Plethora of studies showed that PARP1 can contribute to both gene activation and repression. For example, its interaction with metabolic regulatory transcription factors, such as FOXO1 ([@B72]) and PPARγ ([@B30]), affects genes implicated in mitochondrial respiration and fatty acid oxidation ([@B5]).

In a living system, different tissues can affect each other's homeostasis and therefore give rise to differential physiological phenotypes. This could explain the conflicting results observed in macroH2A1 and PARP1 KO mice. Despite discrepancies, the majority of studies suggest unfavorable effects of PARP1 enzyme on metabolism. On the other hand, macroH2A1.1 is often associated with beneficial metabolic outcomes (**Table [1](#T1){ref-type="table"}**).

The macroH2A1.1-PARP1 Axis
==========================

Although macroH2A and PARP proteins have been studied for decades, the physiological consequences and mechanisms of their interaction are still unclear and require further research. Depending on the relative abundance of the two proteins and the strength of PARP1 activity, their interaction may have at least two different outcomes. On the one hand, macroH2A1.1 can recruit active PARP1 to chromatin and thus act in concert to regulate gene expression. On the other hand, macroH2A1.1 can bind and inhibit PARP1 activity, with global consequences on cellular metabolism. Although an interconnection between macroH2A1.1 and PARP1 was also observed in the context of DNA damage response ([@B79]), the molecular mechanism of such processes needs to be further investigated.

The Effect on Gene Regulation
-----------------------------

MacroH2A1.1 and PARP1 cooperate to repress and activate genes in response to external signals. This is best understood in the context of the transcriptional regulation of the heat shock-inducible *Hsp70.1* gene. In HeLa cells, exogenous macroH2A1.1 was found to recruit PARP1 to the silenced *Hsp70.1* promoter ([@B55]). Heat shock activates PARP1 resulting in significant auto-PARylation and PARylation of target proteins. This leads to the release of both macroH2A1.1 and PARP-1 from chromatin, and as consequence activates the *Hsp70.1* gene ([@B55]). In fibroblasts, the interaction of macroH2A1.1 with activated PARP1 contributes to both positive and negative gene regulation ([@B18]). Mechanistically, macroH2A1.1-bound PARP1 recruits the histone acetyltransferase CBP promoting H2B acetylation of its target genes ([@B18]). Furthermore, macroH2A1.1-PARP1 axis is important for the regulation of SASP (senescence-associated secretory phenotype) genes in cancer cell model ([@B17]). Additionally, macroH2A1.1 facilitates differentiation of 3T3-L1 preadipocytes by inhibiting regulatory genes such as *Wnt10b* ([@B84]). This phenotype was only observed with macroH2A1.1 isoform suggesting the potential implication of macroH2A1.1-PARP1 axis in adipogenesis. In summary, macroH2A1.1-PARP1 axis regulates cellular stress response in a transcription-dependent manner (**Figure [1](#F1){ref-type="fig"}**). Consequently, it affects several physiological outcomes such as cancer, senescence, and possibly adipogenesis.

![Physiological function of the MacroH2A1.1_PARP1 axis. Stressing signals generated during DNA damage repair, senescence, hormonal response, heat shock, or differentiation promote the binding of macroH2A1.1 to activated PARP1 creating the macroH2A1.1-PARP1 axis. On the one hand, when macroH2A1.1 is highly expressed, this interaction leads to the inhibition of PARP1 activity which reduces PARP1 consumption of nuclear NAD+. In this way, the macroH2A1.1-PARP1 axis influences mitochondrial activity through subcellular NAD pools turnover. On the other hand, macroH2A1.1 and active PARP1 act in concert in order to regulate gene expression and as a consequence regulate stress signals response. Crosstalks between those both pathways implicating sirtuin and other PARP enzymes may additionally influence the physiological outcomes of the macroH2A1.1-PARP1 axis. The question marks illustrate the lack of knowledge regarding some steps in this axis pathway.](fgene-09-00417-g001){#F1}

The Effect on NAD^+^ Metabolism
-------------------------------

Beside gene regulation, the macroH2A1.1-PARP1 axis was reported to influence cellular NAD^+^ pools. NAD^+^ is a well-known coenzyme essential for redox reactions in metabolism. Beyond its crucial role in glycolysis and mitochondrial respiration, NAD^+^ is also involved in the regulation of gene expression, DNA repair, calcium signaling, circadian rhythms, lifespan, and cell death (reviewed in [@B13]). The maintenance of NAD^+^ levels is mainly ensured through its salvage which requires much fewer enzymatic reactions than its de novo synthesis from dietary sources (reviewed in [@B80]). The consumption of NAD^+^ by PARPs and sirtuin deacetylases (SIRTs) generates ADP-ribose and NAM (nicotinamide). NAM is subsequently converted into nicotinamide mononucleotide (NMN), which is a major NAD^+^ precursor (**Figure [1](#F1){ref-type="fig"}**). Interestingly, more than 50 years ago, it was shown that NMN addition to liver nuclear extract stimulates PARylation supporting the link between NAD^+^ salvage pathway and PARP1 activity ([@B15]). Since then, NAD^+^ and its salvage pathway have been demonstrated to be essential for nuclear, cytoplasmic, and mitochondrial activities.

A breakthrough appeared with the development of molecular tools able to detect free NAD^+^ ([@B11]) and ATP ([@B39]) in sub-cellular compartments. This allowed for monitoring of how the imbalance of NAD^+^ and ATP in one organelle affects the whole cellular metabolism ([@B87]; [@B71]). Among all PARPs, PARP1 is the major NAD^+^ consumer in the nucleus (reviewed in [@B34]). Prolonged PARP1 activation leads to depletion of cellular NAD^+^ and ATP ([@B38]). As a consequence, this leads to a misbalance of sub-cellular NAD^+^ pools, which results in mitochondrial dysfunction ([@B82]; [@B20]), increased oxidative stress and cell death ([@B83]; [@B91]).

Proliferative cells have high nuclear energy demand and mainly use glycolysis to ensure fast synthesis of nucleic acids. On the other hand, terminally differentiated cells rather rely on mitochondrial respiration in order to maintain tissue functions ([@B47]). In this respect, in commonly used cell model for skeletal muscle differentiation, it was shown that the macroH2A1.1-PARP1 axis protected differentiated myotubes from oxidative stress ([@B54]; [@B67]). Indeed, a decrease of PARP1 protein level and activity was observed during muscle differentiation which was associated with higher resistance to oxidative damage ([@B5]; [@B78]; [@B54]). Furthermore, a splicing switch of macroH2A1 occurs during cell differentiation, which results in the increase of macroH2A1.1 levels ([@B76]; [@B67]). Additionally, our group observed that high abundance of macroH2A1.1 leads to the reduction of nuclear consumption of NAD^+^ by PARP1 in differentiated myotubes. In this way, macroH2A1.1 maintains optimal NAD^+^ and NMN levels in the different cellular compartments, thereby facilitating proper respiratory capacity of mitochondria ([@B67]). Interestingly, dietary supplementation with NMN enhanced mitochondrial oxidative metabolism in mice which was associated with the suppression of age-associated body weight ([@B88]). Following a similar trend, pharmacologic inhibition of PARP1 or its genetic deletion improves mitochondrial function ([@B64]). This happens due to the increase of NAD^+^ availability, which promotes SIRT1 activation and downstream regulation of metabolic genes ([@B5]). In conclusion, the macroH2A1.1-PARP1 axis can influence NAD^+^ metabolism and consequentially the activity of distant organelles, such as mitochondria (**Figure [1](#F1){ref-type="fig"}**). This can occur independently of gene regulation or could involve other NAD^+^ sensitive transcriptional processes.

Conclusion and Future Perspectives
==================================

MacroH2As are commonly studied with respect to their function as transcriptional regulators and epigenome stabilizers. Intriguingly, recent results highlighted a new function of macroH2A1.1, which is to establish adequate threshold for PARP1 activity and help maintain cell energy homeostasis. Future work will be necessary to better understand how different stress signals affect the macroH2A1.1-PARP1 axis and a possible involvement of other partners, such as SIRTs or other PARPs. This new discovery redefines research boundaries of macroH2A field and raises the need to investigate the function of macroH2A considering its effects on both nuclear and whole-cell level. In conclusion, the study of the macroH2A1.1-PARP1 axis could have a great clinical relevance, especially in diseases related to NAD^+^ deficiency, such as sarcopenia and pellagra.
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